Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway

Ren, Yu and Huang, Shuang-shuang and Wang, Xue and Lou, Zhong-guan and Yao, Xu-ping and Weng, Guo-bin (2016) Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway. Iranian Journal of Basic Medical Sciences, 19 (11). pp. 1245-1250.

[img]
Preview
Text
IJBMS_Volume 19_Issue 11_Pages 1245-1250.pdf

Download (1MB) | Preview
Official URL: http://ijbms.mums.ac.ir/article_7826.html

Abstract

Objective(s): Renal cell carcinoma (RCC) is insensitive to conventional chemotherapy. Ginkgetin effectively treats several carcinoma cells. However, little is known about effects of Ginkgetin on RCC. In the present study, using 786-O cells, we evaluate whether Ginkgetin exerts anticancer effects against RCC. Materials and Methods: 786-O cells suspended in the medium containing Ginkgetin were cultured for 24 hr to 72 hr, and then MTT assay was used to study cytotoxic effect of Ginkgetin. Apoptosis in 786-O was measured by an FITC Annexin apoptosis detection kit. Protein expression was detected by Western blotting. 786-O cells with active Janus kinase 2 (JAK2)-Signal transducer and activator of transcription 3 (STAT3) were prepared by stimulant of interleukin-6 (IL-6), whereas 786-O cells with deactivated STAT3 were produced by small interfering RNA (siRNA) STAT3. Results: Ginkgetin suppressed the growth of 786-O in dose and time-dependent manners with IC50 values of 7.23 μM. Ginkgetin induced apoptosis of 786-O cells and increased the levels of caspase-8, caspase-9, and caspase-3. Additionally, Ginkgetin treated 786-O cells showed decreased levels of JAK2 and phosphorylated-STAT3 whether or not IL-6 was pretreated. Interestingly, pretreatment of siRNA STAT3 exerted inhibitory effects on the growth of 786-O cells, and the observation could be further reinforced after the Ginkgetin treatment. Conclusion: Our results indicate Ginkgetin possesses obvious inhibitory effects on the proliferation of 786-O, and this effect is probably due to its inhibition of JAK2/STAT3 pathway. Our findings imply Ginkgetin is a potential therapeutic medicine for RCC.

Item Type: Article
Subjects: QT physiology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 26 Sep 2017 18:14
Last Modified: 26 Sep 2017 18:14
URI: http://eprints.mums.ac.ir/id/eprint/4898

Actions (login required)

View Item View Item